The ArthritisPower Wearable Study

NCT05603806 | Completed

• 1 other identifier: Pro00047954
• Study Type: observational
• Target: 299
• Locations: 1 country
• Sites: 1

Brief Summary

Rheumatoid arthritis patients being seen at one of the participating clinical sites in a U.S. network of community rheumatology practices who are starting treatment on adalimumab or upadacitinib will be enrolled into a 24-week study combining clinical data from physicians, self-reported patient outcomes from the ArthritisPower registry app, and activity and sleep data from a Fitbit wearable device. The primary objective of this study is:

• Evaluate longitudinal associations between biometric sensor data (activity and sleep measures), physician-derived data (including clinical disease activity index (CDAI), Rheumatoid Factor (RF) lab results and other relevant biomarkers, current medications and disease duration), and patient-reported outcomes (PROs) (including PROMIS pain interference, physical function, fatigue, sleep disturbance, satisfaction with participation in discretionary social activities, and anxiety). The secondary objectives of this study are as follows:
• Explore the reliability and predictive validity of biometric sensor data to classify changes in RA disease activity and associated symptoms, including PROs.
• To assess adherence and predictors of adherence with use of biometric sensor
• Assess/track changes in upadacitinib and adalimumab patients using combined physician, PRO and biosensor data.

Conditions

Rheumatoid Arthritis

Keywords

patient-reported outcomes; rheumatoid arthritis; real world evidence; wearable digital technology; real world data; rheumatology; patients; patient-generated health data; mobile technology

Outcome Measures

Primary Outcomes (1)

• Correlations between patient reported outcomes (PROs), wearable data, and physician derived data

  Pearson correlation coefficient between patient reported outcomes, wearable data, and physician derived data PROs include:Daily- Pain NRS 0-10; Fatigue NRS 0-10; Duration of Morning Joint Stiffness Weekly- Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5); Patient Global Assessment; PROMIS Pain Interference CAT; PROMIS Physical Function CAT; PROMIS Fatigue CAT; PROMIS Sleep Disturbance CAT Monthly- PROMIS Satisfaction with Participation in Discretionary Social Activities; PROMIS Anxiety Wearable Data include:Activity- steps, distance, energy expenditure, metabolic equivalents, time walking per day, time in activity intensity per day, active time, aerobic time Heart rate-beats per minute, time in heart rate zones; Sleep-time asleep/restless/awake, and derived variables. Physician derived outcomes include:Clinical Disease Activity Index (CDAI); RA Clinical Labs (Rheumatoid Factor lab results); Current prescription medications for RA; Years since RA diagnosis

  PROs and Wearable Data is collected daily. Physician Derived outcomes are collected at baseline and at follow up appointment at 2-6 months post baseline.

Secondary Outcomes (5)

• Changes in RA disease activity and associated symptoms

  CDAI is collected at baseline and then again at a follow up appointment from 2-6 months after baseline.

• Adherence to PRO measures

  PROs Data is collected daily for up to 6 months

• Adherence to wearing Fitbit

  Wearable Data is collected daily for up to 6 months

• Predictors of adherence

  PROs and Wearable Data is collected daily for up to 6 months

• Changes in upadacitinib and adalimumab patients using combined physician, PRO and biosensor data.

  PROs Data is collected daily from baseline physician appointment until follow up appointment. Physician derived outcomes are collected at baseline and then again at a follow up appointment from 2-6 months after baseline.

Study Arms (1)

RA new treatment starts

Adult rheumatoid arthritis patients starting treatment on adalimumab or upadacitinib

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The investigators will recruit patients from non-academic clinical settings and the American Arthritis and Rheumatology Associates (AARA) physician network, Bendcare. All patients seen and treated by Bendcare AARA clinicians may participate in this study should they fit the eligibility criteria. Physicians at these sites will identify patients for their coordinators to enroll. All participants must be or must become ArthritisPower members in order to be eligible for this study consistent with Investigator previously approved studies.

You may qualify if:

• Age 19 and above who are adults (i.e., the age of majority where they reside)
• Diagnosis of RA by a physician (as indicated by survey screening questions)
• Currently being seen by a U.S. rheumatologist
• Starting on the day of enrollment (with no prior use ever) or soon-to-initiate (i.e. in the next 28 days) upadacitinib or adalimumab for RA
• Ability to walk without the use of assistive devices;
• Have access to a computer or smartphone to take health assessments and a survey;
• Already own a smartphone (iPhone or Android); iPhone 4S and later or Android 4.3 and later
• Are willing to join the ArthritisPower patient registry;
• Are willing to download the ArthritisPower app;
• Are willing to contribute daily and weekly ePROs for at least at 89 days, and health activity tracker data for at least 84 days (lead-in period minimum of 5 days plus main study period 84 days). Some participants may contribute data more than 89 days if there was a lag in receiving their medication and hence later medication start date;
• Are willing to wear the smartwatch while sleeping;
• Are willing to complete the 7-day run-in requirements (i.e. completing daily PRO assessments for at least 5 of 7 days);
• Have started their medication within 30 days of enrolling in the study (i.e. enrolling in ArthritisPower)
• Will not be out of internet access (wifi and/or mobile data) for 4 or more consecutive days during the study; and
• Willing to be contacted by e-mail/text message and/or phone by the study coordinator if participants fail to adhere to the study Protocol or for any study related assistance as required.

Sponsors & Collaborators

• Global Healthy Living Foundation: lead
• University of Alabama at Birmingham: collaborator
• Illumination Health: collaborator

Study Sites (1)

Global Healthy Living Foundation

Upper Nyack, New York, 10960, United States

Location

Related Publications (4)

• Nowell WB, Curtis JR, Nolot SK, Curtis D, Venkatachalam S, Owensby JK, Poon JL, Calvin AB, Kannowski CL, Faries DE, Gavigan K, Haynes VS. Digital Tracking of Rheumatoid Arthritis Longitudinally (DIGITAL) Using Biosensor and Patient-Reported Outcome Data: Protocol for a Real-World Study. JMIR Res Protoc. 2019 Sep 26;8(9):e14665. doi: 10.2196/14665.

  PMID: 31573949 BACKGROUND

• Nowell WB, Curtis D, Thai M, Wiedmeyer C, Gavigan K, Venkatachalam S, Ginsberg S, Curtis JR. Digital Interventions to Build a Patient Registry for Rheumatology Research. Rheum Dis Clin North Am. 2019 May;45(2):173-186. doi: 10.1016/j.rdc.2019.01.009.

  PMID: 30952391 BACKGROUND

• Nowell WB, Curtis JR, Crow-Hercher R. Patient Governance in a Patient-Powered Research Network for Adult Rheumatologic Conditions. Med Care. 2018 Oct;56 Suppl 10 Suppl 1(10 Suppl 1):S16-S21. doi: 10.1097/MLR.0000000000000814.

  PMID: 30074946 BACKGROUND

• Yun H, Nowell WB, Curtis D, H Willig J, Yang S, Auriemma M, Chen L, Filby C, Curtis JR. Assessing Rheumatoid Arthritis Disease Activity With Patient-Reported Outcomes Measurement Information System Measures Using Digital Technology. Arthritis Care Res (Hoboken). 2020 Apr;72(4):553-560. doi: 10.1002/acr.23888.

  PMID: 30927515 BACKGROUND

Related Links

• ArthritisPower

MeSH Terms

Conditions

Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Laura Stradford, MPH

  Global Healthy Living Foundation

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 22, 2022
• First Posted: November 3, 2022
• Study Start: March 1, 2021
• Primary Completion: December 31, 2023
• Study Completion: December 31, 2023
• Last Updated: September 26, 2024

Record last verified: 2024-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)